SB05 (EndoTAG®-1) is approved to conduct Phase III clinical trial in South Korea (MFDS) for pancreatic cancer.
According to the World Health Organization (WHO), approximately 6,036 people died from pancreatic cancer in South Korea in 2015, indicated that 12 per 10 million of people in South Korea died because of pancreatic cancer. The huge unmet medical need in this country is beyond discussion. SynCoreBio is now moving into Phase III clinical trial in South Korea. The trial is expected to be completed by the fourth quarter of the year 2020.
| About SynCore Biotechnology Co., Ltd
SynCore Biotechnology Co., Ltd (“SynCore”) is a biopharmaceutical company focusing on creating values of new drugs by R&D and integration of technology resources. SynCore was established in 2008 and cofounded by Sinphar Group and National Health Research Institute (NHRI). SynCore utilizes and in-licenses the unique technologies from all over the world to develop new drugs for unmet medical needs with great marketing potential. Syncore’s comprehensive pipeline portfolio of new drugs in the area of oncology, ophthalmology, dermatology and infectious diseases. Meet us at:
|